At the last check on Friday, Relay Therapeutics Inc.’s (NASDAQ:RLAY) stock was up $0.6, moving up 5.87 percent to $10.82. The average number of shares traded per day over the past five days has been 623,382 shares. 4 times new highs have been achieved over the past 5 days, with a $0.33 gain in that time frame. In the last twenty days, the average volume was 835,321, while in the previous 50 days, it was 889,956.
Since last month, RLAY stock retreated -2.08%. Shares of the company fell to $9.83 on 08/25/23, the lowest level in the past month. A 52-week high of $33.06 was reached on 02/02/23 after having rallying from a 52-week low of $9.67. Since the beginning of this year, RLAY’s stock price has dropped by -27.58% or -$4.34, and marked a new high 9 times. However, the stock has declined by -67.27% since its 52-week high.
RLAY stock investors should be aware that Relay Therapeutics Inc. (RLAY) stock had its last reported insider trading activity 35 days ago on Jul 28. Bergstrom Donald A, the President, R&D of the company, disposed of 2,683 shares for $11.80 on Jul 28. It resulted in a $31,659 divestment by the insider. Catinazzo Thomas sold 1,693 shares at an average price of $11.80 on Jul 28. The insider now owns 146,136 shares following the transaction. On Jul 28, Chief Legal Officer Adams Brian sold 1,628 shares at $11.80 apiece. The transaction was valued at $19,210.
Valuation Metrics
The stock’s beta is 1.38. Besides these, the trailing price-to-sales (P/S) ratio of 1416.82, the price-to-book (PB) ratio of 1.62.
Financial Health
In the three months ended June 29, Relay Therapeutics Inc.’s quick ratio stood at 12.40, while its current ratio was 12.40, showing that the company is able to pay off its debt. Based on annual data, RLAY earned $300.66 million in gross profit and brought in $1.38 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -31.50%. Return on equity (ROE) for the past 12 months was -37.80%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RLAY’s revenue fell -208.33% to $0.23 million during the quarter, while net income inched up to $0.12 million. While analysts expected Relay Therapeutics Inc. to report -$0.82 quarterly earnings, the actual figure was -$0.81 per share, beating the consensus estimate by 1.20%. During the quarter, the company generated -$106.92 million in EBITDA. The liabilities of Relay Therapeutics Inc. were 151.9 million at the end of its most recent quarter ended June 29, and its total debt was $55.71 million. The value of shareholders’ equity is $122.13 million.
Technical Picture
This quick technical analysis looks at Relay Therapeutics Inc.’s (RLAY) price momentum. With a historical volatility rate of 55.16%, the RSI 9-day stood at 48.97% on 31 August.
With respect to its five-day moving average, the current Relay Therapeutics Inc. price is up by +3.21% percent or $0.33. At present, RLAY shares trade -5.78% below its 20-day simple moving average and -41.18% percent below its 100-day simple moving average. However, the stock is currently trading approximately -10.92% below its SMA50 and -46.38% below its SMA200.
Stochastic coefficient K was 48.62% and Stochastic coefficient D was 46.68%, while ATR was 0.54. Given the Stochastic reading of 60.16% for the 14-day period, the RSI (14) reading has been calculated as 46.68%. As of today, the MACD Oscillator reading stands at 0.05, while the 14-day reading stands at 0.01.
Analyst Ratings
Jefferies upgraded its rating on Relay Therapeutics Inc. (NASDAQ: RLAY) to a Hold in a note to investors on April 20, 2023. The analysts firm previously had an Underperform rating on the stock.Relay Therapeutics Inc. (RLAY) has been rated Buy by analysts. According to 0 brokerage firms, RLAY is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Relay Therapeutics Inc. stock as buy, with 12 recommending it as overweight.
With a median target price of $29.00, the current consensus forecast for the stock is $15.00 – $38.00. Based on these forecasts, analysts predict Relay Therapeutics Inc. (RLAY) will achieve an average price target of $27.42.
